Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.
Raffit Hassan
No relevant relationships to disclose
Thierry Marie Jahan
Research Funding - Morphotek
Hedy Lee Kindler
Research Funding - Morphotek
Lyudmila Bazhenova
No relevant relationships to disclose
Martin Reck
No relevant relationships to disclose
Ira Pastan
No relevant relationships to disclose
Alison Ellis
Employment or Leadership Position - Morphotek
Penny Marie Fatato
Employment or Leadership Position - Morphotek
John Heyburn
Employment or Leadership Position - Morphotek
Charles Schweizer
Employment or Leadership Position - Morphotek
Jeff Parno
Consultant or Advisory Role - Morphotek
Bruce Wallin
Consultant or Advisory Role - Morphotek